中国飞鹤(6186.HK)：期待库存去化完成后经营步入正轨

Core Viewpoint - The company reported a significant decline in revenue and net profit for the year 2025, primarily due to inventory clearance and reduced government subsidies, with expectations for recovery in 2026 driven by improved inventory management and potential positive impacts from fertility subsidies [1][2][3]. Financial Performance - In 2025, the company achieved revenue and net profit of 18.11 billion and 1.94 billion yuan, respectively, representing year-on-year declines of 12.7% and 45.7% [1]. - For the second half of 2025, revenue and net profit were 8.96 billion and 0.94 billion yuan, with declines of 15.9% and 44.6% year-on-year [1]. - The gross margin decreased by 1.3 percentage points to 65.0% for the full year, while the net profit margin fell by 6.5 percentage points to 10.7% [3]. Business Segment Performance - The dairy and nutrition products segment saw a revenue decline of 12.6% to 18.00 billion yuan, while the raw milk business experienced a 27.3% drop to 0.11 billion yuan in 2025 [2]. - The infant formula powder industry continued to face demand pressures, leading to a strategic inventory clearance by the company [2]. Regional Performance - In 2025, the company generated revenue of 17.88 billion yuan in mainland China, 0.18 billion yuan in the U.S., and 0.05 billion yuan in Canada, with year-on-year changes of -13.0%, +11.7%, and +23.3%, respectively [2]. Cost and Efficiency - The company's selling and administrative expense ratios increased significantly, with selling expenses rising by 4.9 percentage points to 39.5% and administrative expenses by 1.2 percentage points to 9.3% in 2025 [3]. - The company is focusing on enhancing channel inventory management and monitoring terminal pricing through digital store management and electronic fencing [2]. Future Outlook - The company anticipates a recovery in operations post-inventory clearance and expects the positive effects of fertility subsidies to materialize [1]. - Revenue forecasts for 2026 and 2027 have been adjusted to 18.84 billion and 19.51 billion yuan, reflecting a downward revision of 11% and 12% from previous estimates [3]. - The estimated earnings per share (EPS) for 2026, 2027, and 2028 are projected to be 0.31, 0.33, and 0.35 yuan, respectively, with a target price of 4.56 HKD based on a 13x price-to-earnings ratio for 2026 [3].